Haemonetics Corporation – NYSE:HAE
Haemonetics stock price today
$53.44
-24.12
-31.11%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 5 hours
Haemonetics stock price monthly change
-14.36%
month
Haemonetics stock price quarterly change
-14.36%
quarter
Haemonetics stock price yearly change
-10.69%
year
Haemonetics key metrics
Market Cap | 3.77B |
Enterprise value | 4.78B |
P/E | 46.16 |
EV/Sales | 4.23 |
EV/EBITDA | 20.43 |
Price/Sales | 3.75 |
Price/Book | 5.46 |
PEG ratio | -1.00 |
EPS | 1.61 |
Revenue | 1.17B |
EBITDA | 229.19M |
Income | 82.72M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 8.48% |
Oper. margin | 12.4% |
Gross margin | 52.7% |
EBIT margin | 12.4% |
EBITDA margin | 19.55% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHaemonetics stock price history
Haemonetics stock forecast
Haemonetics financial statements
Average Price Target
$107
Potential upside: 100.22%
Analysts Price target
Financials & Ratios estimates
| Jan 2022 | 259.76M | 23.23M | 8.94% |
|---|---|---|---|
| Apr 2022 | 265.00M | 9.74M | 3.68% |
| Apr 2023 | 304.41M | 29.38M | 9.65% |
| Mar 2024 | 343.29M | 20.36M | 5.93% |
| Oct 2022 | 1865112000 | 1.13B | 60.91% |
|---|---|---|---|
| Dec 2022 | 1878066000 | 1.10B | 58.68% |
| Apr 2023 | 1934825000 | 1.11B | 57.72% |
| Mar 2024 | 2195591000 | 1.23B | 56.28% |
| Jan 2022 | 62.43M | -15.46M | -2.03M |
|---|---|---|---|
| Apr 2022 | 68.05M | -34.51M | -8.76M |
| Apr 2023 | 79.61M | -18.00M | -1.60M |
| Mar 2024 | 64.08M | -13.05M | -63.50M |
Haemonetics alternative data
| Aug 2023 | 3,034 |
|---|---|
| Sep 2023 | 3,034 |
| Oct 2023 | 3,034 |
| Nov 2023 | 3,034 |
| Dec 2023 | 3,034 |
| Jan 2024 | 3,034 |
| Feb 2024 | 3,034 |
| Mar 2024 | 3,034 |
| Apr 2024 | 3,034 |
| May 2024 | 3,034 |
| Jun 2024 | 3,657 |
| Jul 2024 | 3,657 |
Haemonetics other data
86.36%
-13.64%
of HAE is owned by hedge funds
241
+2
44.63M
-7.06M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 0 | 2538 |
| Jul 2023 | 0 | 4928 |
| Sep 2023 | 0 | 12748 |
| May 2024 | 0 | 4793 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BASIL MICHELLE L officer: EVP and .. | Common Stock | 985 | $96.14 | $94,698 | ||
Option | STRONG STEWART W officer: President, Global Hosp.. | Common Stock | 2,410 | $57.6 | $138,816 | ||
Sale | STRONG STEWART W officer: President, Global Hosp.. | Common Stock | 733 | $96.04 | $70,397 | ||
Option | STRONG STEWART W officer: President, Global Hosp.. | Non-qualified Stock Option (Right to Buy) | 2,410 | $57.6 | $138,816 | ||
Sale | LLORENS JOSEP officer: EVP, Glo.. | Common Stock | 770 | $96.14 | $74,028 | ||
Sale | LINGAMNENI ANILA officer: EVP, Chi.. | Common Stock | 2,305 | $95 | $218,975 | ||
Sale | STRONG STEWART W officer: President, Global Hosp.. | Common Stock | 228 | $90.65 | $20,668 | ||
Sale | LINGAMNENI ANILA officer: EVP, Chi.. | Common Stock | 2,305 | $90 | $207,450 | ||
Sale | DOCKENDORFF CHARLES J director | Common Stock | 10,215 | $87.68 | $895,651 | ||
Option | LLORENS JOSEP officer: EVP, Glo.. | Common Stock | 2,537 | $57.6 | $146,131 |
| Patent |
|---|
Application Thrombelastography Device, Heating Apparatus, Blood Coagulation Analysis System and Rotational Angle Measurement Method Filling date: 19 May 2022 Issue date: 8 Sep 2022 |
Application Filling date: 29 Dec 2021 Issue date: 21 Apr 2022 |
Application Filling date: 28 Oct 2021 Issue date: 17 Feb 2022 |
Application Filling date: 26 Aug 2019 Issue date: 25 Nov 2021 |
Application Filling date: 11 Sep 2019 Issue date: 18 Nov 2021 |
Grant Filling date: 20 Jul 2016 Issue date: 2 Nov 2021 |
Application Filling date: 26 Aug 2019 Issue date: 28 Oct 2021 |
Application Filling date: 26 Aug 2019 Issue date: 28 Oct 2021 |
Application Filling date: 26 Aug 2019 Issue date: 21 Oct 2021 |
Application Filling date: 17 Jun 2021 Issue date: 7 Oct 2021 |
| Quarter | Transcript |
|---|---|
| Q4 2024 10 May 2024 | Q4 2024 Earnings Call Transcript |
| Q3 2024 8 Feb 2024 | Q3 2024 Earnings Call Transcript |
| Q2 2024 3 Nov 2023 | Q2 2024 Earnings Call Transcript |
| Q1 2024 8 Aug 2023 | Q1 2024 Earnings Call Transcript |
Haemonetics: Solid Performance Of This Blood Play
Haemonetics Offers Relatively Rare Momentum In A Tough Medical Device Environment
Intellia Therapeutics: The Future Is Here
Haemonetics Corporation: Premium Blood Play
Haemonetics: Attracting Investment Through Capital Recycling Initiatives
Haemonetics Executing Well, But Valuation Dogged By Concerns About A Large Customer
Haemonetics: Earnings Rate Of Change Justifies High Multiples
Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect
Haemonetics Leveraging Strong Recovery Trends And Repositioning For The Future
-
What's the price of Haemonetics stock today?
One share of Haemonetics stock can currently be purchased for approximately $53.44.
-
When is Haemonetics's next earnings date?
Unfortunately, Haemonetics's (HAE) next earnings date is currently unknown.
-
Does Haemonetics pay dividends?
No, Haemonetics does not pay dividends.
-
How much money does Haemonetics make?
Haemonetics has a market capitalization of 3.77B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.01% to 1.31B US dollars.
-
What is Haemonetics's stock symbol?
Haemonetics Corporation is traded on the NYSE under the ticker symbol "HAE".
-
What is Haemonetics's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Haemonetics?
Shares of Haemonetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Haemonetics's key executives?
Haemonetics's management team includes the following people:
- Mr. Christopher A. Simon Chief Executive Officer, Pres & Director(age: 61, pay: $2,030,000)
- Mr. William P. Burke Chief Financial Officer & Executive Vice President(age: 57, pay: $925,860)
- Ms. Anila Lingamneni Executive Vice President & Chief Technology Officer(age: 58, pay: $845,330)
- Ms. Michelle L. Basil Executive Vice President, Gen. Counsel & Sec.(age: 53, pay: $815,710)
- Mr. Josep Lluis Llorens Senior Vice President of Global Manufacturing & Supply Chain(age: 63, pay: $700,750)
-
How many employees does Haemonetics have?
As Jul 2024, Haemonetics employs 3,657 workers, which is 21% more then previous quarter.
-
When Haemonetics went public?
Haemonetics Corporation is publicly traded company for more then 34 years since IPO on 10 May 1991.
-
What is Haemonetics's official website?
The official website for Haemonetics is haemonetics.com.
-
Where are Haemonetics's headquarters?
Haemonetics is headquartered at 125 Summer Street, Boston, MA.
-
How can i contact Haemonetics?
Haemonetics's mailing address is 125 Summer Street, Boston, MA and company can be reached via phone at +7 818487100.
-
What is Haemonetics stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Haemonetics in the last 12 months, the avarage price target is $107. The average price target represents a 100.22% change from the last price of $53.44.
Haemonetics company profile:
Haemonetics Corporation
haemonetics.comExchange:
NYSE
Full time employees:
3,657
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
125 Summer Street
Boston, MA 02110
Boston, MA 02110
CIK: 0000313143
ISIN: US4050241003
CUSIP: 405024100
